New PET tracer aims to sharpen prostate cancer detection

NCT ID NCT05324332

Recruiting now Diagnosis Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares a new radioactive tracer, 68Ga-P16-093, with the standard tracer 68Ga-PSMA-11 for PET/CT imaging in 50 men with untreated prostate cancer. The goal is to see which tracer better detects tumors and their spread. Participants will receive both tracers within a week, and the number of tumors detected will be compared.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-P16-093 and 68Ga-PSMA-11 (radioactive tracers for PET imaging)
What this could lead to: If successful, this could lead to a more accurate imaging method for detecting prostate cancer and its spread.
What could go wrong: This is a small, early pilot study with only 50 participants. The new tracer may not prove better than the existing one, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.